Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 5
2006 2
2007 2
2008 3
2011 2
2012 1
2013 3
2014 5
2015 6
2016 3
2017 9
2018 11
2019 9
2020 19
2021 19
2022 18
2023 17
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Pelaia C, et al. Among authors: pelaia g. Front Immunol. 2020 Nov 30;11:603312. doi: 10.3389/fimmu.2020.603312. eCollection 2020. Front Immunol. 2020. PMID: 33329598 Free PMC article. Review.
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus.
Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, Allegrini C, Antonelli A, Aruanno A, Bacci E, Bagnasco D, Beghè B, Bonavia M, Bonini M, Brussino L, Caiaffa MF, Calabrese C, Camiciottoli G, Caminati M, Caruso C, Cavallini M, Chieco Bianchi F, Conte ME, Corsico AG, Cosmi L, Costantino M, Costanzo G, Crivellaro M, D'Alò S, D'Amato M, Detoraki A, Di Proietto MC, Facciolongo NC, Ferri S, Fierro V, Foschino MP, Latorre M, Lombardi C, Macchia L, Milanese M, Montagni M, Parazzini EM, Parente R, Passalacqua G, Patella V, Pelaia G, Pini L, Puggioni F, Ricciardi L, Ridolo E, Rolo J, Scichilone N, Scioscia G, Senna G, Solidoro P, Varricchi G, Vianello A, Yacoub MR, Yang B. Canonica GW, et al. Among authors: pelaia g. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3629-3637. doi: 10.1016/j.jaip.2023.07.041. Epub 2023 Aug 7. J Allergy Clin Immunol Pract. 2023. PMID: 37558162 Free article. Review.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Crimi N, Scichilone N, Pelaia G, Carpagnano GE, Crimi C. Nolasco S, et al. Among authors: pelaia g. Front Immunol. 2023 Jun 30;14:1204444. doi: 10.3389/fimmu.2023.1204444. eCollection 2023. Front Immunol. 2023. PMID: 37457743 Free PMC article.
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P. Jackson DJ, et al. Among authors: pelaia g. Eur Respir J. 2024 Jul 11;64(1):2301521. doi: 10.1183/13993003.01521-2023. Print 2024 Jul. Eur Respir J. 2024. PMID: 38575162 Free PMC article.
Dupilumab for the treatment of asthma.
Pelaia C, Vatrella A, Gallelli L, Terracciano R, Navalesi P, Maselli R, Pelaia G. Pelaia C, et al. Among authors: pelaia g. Expert Opin Biol Ther. 2017 Dec;17(12):1565-1572. doi: 10.1080/14712598.2017.1387245. Epub 2017 Oct 8. Expert Opin Biol Ther. 2017. PMID: 28990423 Review.
Interleukin-5 in the Pathophysiology of Severe Asthma.
Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. Pelaia C, et al. Among authors: pelaia g. Front Physiol. 2019 Dec 17;10:1514. doi: 10.3389/fphys.2019.01514. eCollection 2019. Front Physiol. 2019. PMID: 31920718 Free PMC article. Review.
Type 2 severe asthma: pathophysiology and treatment with biologics.
Pelaia C, Melhorn J, Hinks TS, Couillard S, Vatrella A, Pelaia G, Pavord ID. Pelaia C, et al. Among authors: pelaia g. Expert Rev Respir Med. 2024 Jul;18(7):485-498. doi: 10.1080/17476348.2024.2380072. Epub 2024 Jul 23. Expert Rev Respir Med. 2024. PMID: 38994712 Review.
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE. Portacci A, et al. Among authors: pelaia g. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37908397 Free PMC article.
141 results